Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)
Rhea-AI Summary
Nasus Pharma (NYSE:NSRX) reported positive preclinical pharmacokinetic and safety results for NS003, its intranasal powder ondansetron for chemotherapy and post-operative nausea and vomiting.
In animal studies, NS003 showed a PK profile comparable to intravenous ondansetron and a favorable safety profile, supporting a planned first-in-human PK study in Q3 2026.
Positive
- NS003 intranasal ondansetron showed pharmacokinetic profile comparable to intravenous formulation in animal study
- Toxicology study found favorable safety for NS003 at four times the test dose with no adverse effects
- First-in-human pharmacokinetic study of NS003 planned to start in the third quarter of 2026
- Pivotal study of intranasal anaphylaxis candidate NS002 targeted to begin in the fourth quarter of 2026
Negative
- None.
News Market Reaction – NSRX
In the Jun 9 session, NSRX declined 0.34%, reflecting a mild negative market reaction. Argus tracked a peak move of +5.1% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 01 | KOL event announcement | Neutral | -0.6% | Announcement of virtual KOL event to discuss NS002 Phase 2 data. |
| May 01 | Investor conferences | Neutral | +1.9% | Management participation in New York investor conferences with 1x1 meetings. |
| Mar 25 | Pipeline and results update | Positive | +10.8% | Positive NS002 Phase 2 topline data and annual results with pipeline timeline. |
| Mar 16 | Phase 2 topline data | Positive | -40.6% | NS002 Phase 2 data showing faster epinephrine delivery versus EpiPen. |
| Mar 09 | Data presentation notice | Neutral | -15.4% | Notice of upcoming NS002 Phase 2 topline analysis presentation and webcast. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
NSRX often reacts strongly to clinical milestones, with one notable divergence where positive Phase 2 NS002 data coincided with a 40.6% decline. Other corporate or event updates have shown modest, generally aligned moves.
Over the last six months, Nasus Pharma has focused on advancing its intranasal pipeline. Positive Phase 2 data for NS002 on Mar 16, 2026 was followed by a 40.6% drop, while a broader business update and NS002 progression on Mar 25, 2026 saw shares gain 10.84%. Conference participation in early May produced a small positive reaction. More recently, a KOL event announcement for NS002 on Jun 1, 2026 had little price impact. Today’s NS003 preclinical results extend this intranasal platform story.
Key Terms
pharmacokinetic medical
intranasal medical
intravenous medical
tmax medical
area under the curve (auc) medical
toxicology medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Study Comparing Intranasal Powder Formulation of Ondansetron Demonstrates Comparable Pharmacokinetic Profile to Intravenous Ondansetron in Animal Study;
Program to Advance to First-in-Human PK Study in Third Quarter of 2026
TEL AVIV, Israel, June 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced positive results from a preclinical pharmacokinetic (“PK”) and safety study of NS003, the Company’s proprietary intranasal powder formulation of ondansetron being developed for chemotherapy and post-operative nausea and vomiting.
Ondansetron is one of the most widely used therapies for chemotherapy-induced nausea and vomiting. In 2023, more than 12 million prescriptions were dispensed to over 6 million patients. Zofran (ondansetron) peak sales exceeded
The study compared NS003 to the intravenous (“IV”) formulation in an animal study. Data showed that NS003 had a PK profile comparable to IV, with similar time to maximum concentration (Tmax) and area under the curve (AUC) results. In a separate toxicology study, NS003 demonstrated a favorable safety profile at four times the test dose, with no adverse effects observed. With this milestone achieved, Nasus Pharma is now preparing to initiate a first-in-human PK study in the third quarter of 2026.
“These results represent a significant milestone for our pipeline programs as well as a further demonstration of the potential of our Nasax platform,” said Dan Teleman, Chief Executive Officer of Nasus Pharma. “Approximately 1 million patients in the United States receive chemotherapy annually, 60–
About Nasus Pharma
Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus Pharma’s intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle-free, easy-to-use alternatives. Nasus Pharma’s proprietary powder-based intranasal (“PBI”) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity’s rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products. For further information about the Company, please visit www.nasuspharma.com or follow on Twitter (X) or LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. Words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will”, “would,” or the negative of these words, similar expressions or variations of such words are intended to identify forward-looking statements. For example, Nasus Pharma is using forward-looking statements in this press release when it discusses: the planned initiation and timing of a first-in-human PK study and trial for NS003, the timing of the NS002 pivotal study, expected clinical and development milestones, and the expansion of the Company’s product portfolio. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Forward-looking statements are based on the Company’s current expectations and are subject to uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on March 25, 2026. Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.
Corporate Contact
Nasus Pharma Ltd. Israel
info@nasuspharma.com
Investors Contact
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
